Home LiteratureArticle Details
PMID: 15809227 Published · epublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.

Nucleic acids research ·Vol. 33 ·No. 6 ·2005-00-00 ·Pages 1913-23

Langlois MA, Beale RC, Conticello SG, Neuberger MS

Abstract

Human APOBEC3F and APOBEC3G are double-domained deaminases that can catalyze dC-->dU deamination in HIV-1 and MLV retroviral DNA replication intermediates, targeting T-C or C-C dinucleotides, respectively. HIV-1 antagonizes their action through its vif gene product, which has been shown (at least in the case of APOBEC3G) to interact with the N-terminal domain of the deaminase, triggering its degradation. Here, we compare APOBEC3F and APOBEC3G to APOBEC3C, a single-domained deaminase that can also act on both HIV-1 and MLV. We find that whereas APOBEC3C contains all the information necessary for both Vif-binding and cytidine deaminase activity in a single domain, it is the C-terminal domain of APOBEC3F and APOBEC3G that confer their target site specificity for cytidine deamination. We have exploited the fact that APOBEC3C, whilst highly homologous to the C-terminal domain of APOBEC3F, exhibits a distinct target site specificity (preferring Y-C dinucleotides) in order to identify residues in APOBEC3F that might affect its target site specificity. We find that this specificity can be altered by single amino acid substitutions at several distinct positions, suggesting that the strong dependence of APOBEC3-mediated deoxycytidine deamination on the 5'-flanking nucleotide is sensitive to relatively subtle changes in the APOBEC3 structure. The approach has allowed the isolation of APOBEC3 DNA mutators that exhibit novel target site preferences.

MeSH Terms
APOBEC-3G Deaminase Amino Acid Substitution Anti-Retroviral Agents/chemistry,pharmacology Cytidine Deaminase/chemistry,genetics,pharmacology Cytosine Deaminase/chemistry,genetics,pharmacology DNA Mutational Analysis DNA, Viral/chemistry,drug effects,metabolism Humans Leukemia Virus, Murine/drug effects,genetics Nucleoside Deaminases Proteins/chemistry,genetics,pharmacology Recombinant Fusion Proteins/chemistry,metabolism Repressor Proteins Substrate Specificity
Chemicals
Anti-Retroviral Agents DNA, Viral Proteins Recombinant Fusion Proteins Repressor Proteins Nucleoside Deaminases APOBEC3F protein, human Cytosine Deaminase APOBEC-3G Deaminase APOBEC3C protein, human APOBEC3G protein, human Cytidine Deaminase
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Langlois Marc-André
Medical Research Council Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry Hills Road, Cambridge CB2 2QH, UK.
Beale Rupert C L
Conticello Silvestro G
Neuberger Michael S
References (65)
65 references, click to expand
  1. G to A hypermutation of hepatitis B virus.
    Hepatology. 2005 Mar;41(3):626-33 PMID: 15726649
  2. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.
    J Biol Chem. 2003 Nov 7;278(45):44412-6 PMID: 12970355
  3. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Nat Med. 2003 Nov;9(11):1404-7 PMID: 14528300
  4. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Nat Med. 2003 Nov;9(11):1398-403 PMID: 14528301
  5. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
    Science. 2003 Nov 7;302(5647):1056-60 PMID: 14564014
  6. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
    Curr Biol. 2003 Nov 11;13(22):2009-13 PMID: 14614829
  7. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo.
    J Mol Biol. 2004 Mar 26;337(3):585-96 PMID: 15019779
  8. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).
    Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3927-32 PMID: 14978281
  9. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor.
    Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3770-4 PMID: 14999100
  10. Inhibition of hepatitis B virus replication by APOBEC3G.
    Science. 2004 Mar 19;303(5665):1829 PMID: 15031497
  11. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action.
    J Biol Chem. 2004 Apr 9;279(15):14481-3 PMID: 14966139
  12. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5652-7 PMID: 15054139
  13. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.
    Cell. 2000 Sep 1;102(5):553-63 PMID: 11007474
  14. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.
    J Virol. 2001 Sep;75(17):7973-86 PMID: 11483742
  15. The structure of Escherichia coli cytosine deaminase.
    J Mol Biol. 2002 Jan 25;315(4):687-97 PMID: 11812140
  16. Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas.
    Nature. 2002 Feb 14;415(6873):802-6 PMID: 11823785
  17. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.
    Genomics. 2002 Mar;79(3):285-96 PMID: 11863358
  18. Sustained G-->A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome.
    J Gen Virol. 2002 Apr;83(Pt 4):801-5 PMID: 11907329
  19. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter.
    Hum Gene Ther. 2002 May 1;13(7):803-13 PMID: 11975847
  20. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
    Nature. 2002 Aug 8;418(6898):646-50 PMID: 12167863
  21. Restriction of lentivirus in monkeys.
    Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11920-5 PMID: 12154231
  22. Generation and iterative affinity maturation of antibodies in vitro using hypermutating B-cell lines.
    Nat Biotechnol. 2002 Nov;20(11):1129-34 PMID: 12379869
  23. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators.
    Mol Cell. 2002 Nov;10(5):1247-53 PMID: 12453430
  24. An evolutionarily conserved target motif for immunoglobulin class-switch recombination.
    Nat Immunol. 2004 Dec;5(12):1275-81 PMID: 15531884
  25. Immunity through DNA deamination.
    Trends Biochem Sci. 2003 Jun;28(6):305-12 PMID: 12826402
  26. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    Nature. 2003 Jul 3;424(6944):94-8 PMID: 12808465
  27. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Nature. 2003 Jul 3;424(6944):99-103 PMID: 12808466
  28. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation.
    Nature. 2003 Jul 3;424(6944):103-7 PMID: 12819663
  29. Good to CU.
    Nature. 2003 Jul 3;424(6944):21-2 PMID: 12840737
  30. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Cell. 2003 Jul 11;114(1):21-31 PMID: 12859895
  31. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Mol Cell. 2003 Sep;12(3):591-601 PMID: 14527406
  32. Death and the retrovirus.
    Trends Mol Med. 2003 Oct;9(10):409-13 PMID: 14557052
  33. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business.
    Trends Genet. 2003 Apr;19(4):207-16 PMID: 12683974
  34. Transcription-targeted DNA deamination by the AID antibody diversification enzyme.
    Nature. 2003 Apr 17;422(6933):726-30 PMID: 12692563
  35. Hypermutation of HIV-1 DNA in the absence of the Vif protein.
    Science. 2003 May 16;300(5622):1112 PMID: 12750511
  36. DNA deamination mediates innate immunity to retroviral infection.
    Cell. 2003 Jun 13;113(6):803-9 PMID: 12809610
  37. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
    Nat Struct Mol Biol. 2004 May;11(5):435-42 PMID: 15098018
  38. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
    J Virol. 2004 Jun;78(11):6073-6 PMID: 15141007
  39. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.
    EMBO J. 2004 Jun 16;23(12):2451-8 PMID: 15152192
  40. Rapid evolution of primate antiviral enzyme APOBEC3G.
    Hum Mol Genet. 2004 Aug 15;13(16):1785-91 PMID: 15198990
  41. The interaction between HIV-1 Gag and APOBEC3G.
    J Biol Chem. 2004 Aug 6;279(32):33177-84 PMID: 15159405
  42. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
    Curr Biol. 2004 Aug 10;14(15):1385-91 PMID: 15296757
  43. Cytidine deamination of retroviral DNA by diverse APOBEC proteins.
    Curr Biol. 2004 Aug 10;14(15):1392-6 PMID: 15296758
  44. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.
    J Biol Chem. 2004 Aug 13;279(33):34083-6 PMID: 15215254
  45. Comment on "Inhibition of hepatitis B virus replication by APOBEC3G".
    Science. 2004 Sep 3;305(5689):1403; author reply 1403 PMID: 15353783
  46. HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles.
    Biochem Biophys Res Commun. 2004 Aug 27;321(3):566-73 PMID: 15358144
  47. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.
    PLoS Biol. 2004 Sep;2(9):E275 PMID: 15269786
  48. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
    Virology. 2004 Oct 25;328(2):163-8 PMID: 15464836
  49. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
    J Virol. 2004 Nov;78(21):11841-52 PMID: 15479826
  50. Further investigation of simian immunodeficiency virus Vif function in human cells.
    J Virol. 2004 Nov;78(21):12041-6 PMID: 15479843
  51. Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes.
    J Virol. 1991 Apr;65(4):1779-88 PMID: 2002543
  52. A new type of G-->A hypermutation affecting human immunodeficiency virus.
    AIDS Res Hum Retroviruses. 1993 Sep;9(9):833-8 PMID: 7504935
  53. Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex.
    J Mol Biol. 1994 Jan 14;235(2):635-56 PMID: 8289286
  54. Cloning and mutagenesis of the rabbit ApoB mRNA editing protein. A zinc motif is essential for catalytic activity, and noncatalytic auxiliary factor(s) of the editing complex are widely distributed.
    J Biol Chem. 1994 Aug 26;269(34):21725-34 PMID: 8063816
  55. Evolutionary origins of apoB mRNA editing: catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site.
    Cell. 1995 Apr 21;81(2):187-95 PMID: 7736571
  56. A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G-->A hypermutation during negative-strand viral DNA synthesis.
    Virology. 1995 Apr 20;208(2):601-9 PMID: 7747432
  57. Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity.
    J Biol Chem. 1995 Jun 16;270(24):14768-75 PMID: 7782343
  58. Codon bias targets mutation.
    Nature. 1995 Aug 31;376(6543):732 PMID: 7651532
  59. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.
    Science. 1996 Apr 12;272(5259):263-7 PMID: 8602510
  60. Cytidine deaminases from B. subtilis and E. coli: compensating effects of changing zinc coordination and quaternary structure.
    Biochemistry. 1999 Sep 21;38(38):12258-65 PMID: 10493793
  61. Biochemical analysis of hypermutational targeting by wild type and mutant activation-induced cytidine deaminase.
    J Biol Chem. 2004 Dec 3;279(49):51612-21 PMID: 15371439
  62. Evolution of new nonantibody proteins via iterative somatic hypermutation.
    Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16745-9 PMID: 15556995
  63. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases.
    Mol Biol Evol. 2005 Feb;22(2):367-77 PMID: 15496550
  64. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
    J Biol Chem. 2004 Dec 17;279(51):53379-86 PMID: 15466872
  65. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Curr Biol. 2005 Jan 26;15(2):166-70 PMID: 15668174
Article Info
Journal
Nucleic acids research
Abbr.
Nucleic Acids Res
ISSN
1362-4962
Published
2005-00-00
Epub
2005-00-04
Pages
1913-23
Language
English
Region
England
NLM ID
0411011
PMCID
PMC1074398
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com